A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of SH-1028 with
Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with
Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours
harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene.